Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $270.6 million.

  • Ani Pharmaceuticals' Total Current Liabilities rose 42.45% to $270.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.6 million, marking a year-over-year increase of 42.45%. This contributed to the annual value of $193.7 million for FY2024, which is 33.13% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Total Current Liabilities is $270.6 million, which was up 14.24% from $236.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Total Current Liabilities ranged from a high of $270.6 million in Q3 2025 and a low of $79.5 million during Q1 2022.
  • Over the past 3 years, Ani Pharmaceuticals' median Total Current Liabilities value was $145.5 million (recorded in 2023), while the average stood at $172.6 million.
  • In the last 5 years, Ani Pharmaceuticals' Total Current Liabilities fell by 3.91% in 2022 and then soared by 69.19% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $87.5 million in 2021, then climbed by 13.60% to $99.4 million in 2022, then surged by 46.30% to $145.5 million in 2023, then skyrocketed by 33.13% to $193.7 million in 2024, then spiked by 42.45% to $270.6 million in 2025.
  • Its last three reported values are $270.6 million in Q3 2025, $236.8 million for Q2 2025, and $201.8 million during Q1 2025.